Award Number: DAMD17-01-1-0015

TITLE: Role of IKKs and Transcription Factor NF-κB in Prostate Tumorigenesis

PRINCIPAL INVESTIGATOR: Irina V. Budunova, M.D., Ph.D.

CONTRACTING ORGANIZATION: AMC Cancer Research Center
Lakewood, Colorado 80214

REPORT DATE: May 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Role of IKKs and Transcription Factor NF-κB in Prostate Tumorigenesis

Irina V. Budunova, M.D., Ph.D.

AMC Cancer Research Center
Lakewood, Colorado 80214
E-Mail: budunovai@amc.org

The goal of this project is to understand the role of IKK kinases and NF-κB "survival signaling" pathway in tumorigenesis in prostate. In our previous studies we found that NF-κB was constitutively activated in human androgen-independent prostate carcinoma (PC) cell lines. During the current funding period we found that one of the IKKs, IKKe was only expressed in androgen-independent PC cells with high level of constitutively active NF-κB. We obtained experimental evidence that IKKe could be involved in the NF-κB induction in PC cells through a positive feedback loop. We also found that the conditioned medium from PC cells induced NF-κB in cells with low level of NF-κB activity through secreted proteinaceous factor. These data strongly suggest that NF-κB activity in androgen-independent PC cells may be mediated through an autocrine/paracrine loops. We have generated 175 clones of PC cells transfected with d.n. mutants of different IKKs. We have assessed the effect of d.n. IKK mutants on NF-κB function in PC cells transfected with d.n. mutants of different IKKs. We have assessed the effect of d.n. IKK mutants on NF-κB in clones with the highest level of d.n. IKK expression. The IKKα did not significantly affect NF-κB function in PC cells; IKKe d.n. mutant moderately affected NF-κB activation by selective NF-κB inducers; IKKβ and IKKγ mutants significantly blocked transcriptional activity of NF-κB in PC cells.
# Table of Contents

- Cover .................................................................................. 1
- SF 298 .............................................................................. 2
- Table of Contents ............................................................... 3
- Introduction ....................................................................... 4
- Body .................................................................................. 4
- Key Research Accomplishments ........................................ 5
- Reportable Outcomes .......................................................... 6
- Conclusions ........................................................................ 6
- References ........................................................................... 6
- Appendices .......................................................................... 7-20
Introduction

The overall goal of this project is to understand the role of upstream IκB kinases (IKK) and NF-κB "survival signaling" pathway in tumorigenesis in prostate. During first year we found that NF-κB was constitutively activated in human androgen-independent PC cell lines due to the constitutive activation of IKKα/β kinases. During the current funding period we continued to study the mechanisms of constitutive NF-κB activation in PC cells, and also as was planned, focused on the stable transfection of PC cells with d.n. mutants of IKKα, IKKβ, and IKKe. We have added to the panel of IKKs under study IKKy (also called NEMO), an important component of the IKK complex essential for NF-kappaB activation (Yamaoka et al., 1998, Israel, 2000). Our results indicate that there are positive feedback loops as well as autocrine/paracrine loops involved in constitutive activation of NF-κB in PC cells. We have obtained the experimental evidence that IKKe is strongly involved in constitutive activation of NF-κB in androgen-independent PC cells. Our studies have resulted in publication of one peer-reviewed article. One more manuscript has been submitted. The following describes progress made in this year.

Body

As was proposed we focused during second year on the tasks 6-8 pertinent to the part of the Specific Aim 1 of proposal as well as to the part of Specific Aim 2. We have also conducted experiments to elucidate the additional mechanisms of constitutive NF-κB activation in PC cells.

Our mechanistic studies were more profoundly focused on the inducible IKKe (also called IKKi) - the only IKK whose activity is regulated by its expression Shimada et al., 1999, Peters et al., 2000). We found that IKKe was strongly expressed only in androgen-independent PC cells (PC3 and DU145) with high level of constitutively active NF-κB but not in androgen-dependent PC cell lines and primary prostate epithelial cells (Yao et al., 2002). Immunostaining also revealed that IKKi was expressed in human prostate carcinomas. Treatment of PC cells with NF-kappaB inducers such as IL-1 and TNF-α resulted in a rapid induction of IKKe (Yao et al., 2002). Transient transfection of different PC cell lines with IKKe w.t. resulted in activation of kB.Luciferase reporter, whereas IKKe dominant negative (d.n.) mutant K38A suppressed basal NF-κB activity in PC cells. These data provide experimental evidence that IKKe could be involved in the regulation of NF-κB activity in PC cells through a positive feedback loop.

We also found that the conditioned medium from PC3 cells with activated NF-κB, induced NF-κB in LNCaP cells with low level of NF-κB activity. Conditioned medium taken from PC3 cells induced IκBα phosphorylation as well as κB DNA-binding in LNCaP cells (Gasparian et al., 2002). It also increased the expression of endogenous κB-responsive genes such as IκB-α and IL6. Boiling and multiple freezing/thawing of PC3 conditioned media eliminated its effect on κB DNA-binding. This suggests that secreted NF-κB inducer is a proteinaceous factor. All together these data allowed us to advance
the hypothesis that NF-κB activity in androgen-independent PC cells may be mediated through an autocrine/paracrine loop.

As planned, during the current funding period we focused on the stabile transfections of prostate carcinoma cell lines with dominant negative (d.n.) constructs of upstream kinases IKKα, IKKβ, and IKKε. We have also added to the panel of IKKs under study IKKy (also called NEMO), an important component of the IKK complex essential for NF-κB activation. We have generated more than 95 clones of DU145 and more than 80 clones of PC3 cells transfected with d.n. mutants of different IKKs. We have selected positive clones with the highest level of transgene expression and assessed the effect of d.n. IKK mutants on NF-κB function in PC cells using electromobility shift assay (EMSA), Northern blotting for endogenous κB-responsive gene expression, and transient transfection with κB-Luciferase reporters. We also studied the effect of IKK d.n. mutant stable expression on IkB-α degradation induced by different κB inducers such as TNF-α, IL-1, TPA and LPS. The obtained results suggest that IKKα d.n. mutant did not strongly affect NF-κB function in PC cells. We found that in PC clones transfected with IKKε d.n. mutant constitutive expression of endogenous κB-responsive genes IkB-α and IL6 was moderately decreased (Yao et al., 2002). The IKKε d.n. mutant also moderately affected NF-κB activation by selective NF-κB inducers such as IL-1 and TPA (Yao et al., 2002). On the other hand, IKKε d.n. mutant did not affect activation of NF-κB-binding by TNF-α even though the degradation of IkB-α in IKKε d.n.-transfected cells was inhibited in comparison to parental and empty vector-transfected PC3 cells. Our experiments have revealed that the expression of endogenous κB-responsive genes was dramatically inhibited in PC3 clones stably transfected with d.n. IKKy and d.n. IKKβ mutants. The effect of IKKy d.n. and IKKβ d.n. mutants on κB DNA binding is currently under study.

Key Research Accomplishments

♦ We found that IKKε is highly expressed in human androgen-independent PC cell lines and human prostate carcinomas.

♦ Our experimental data clearly suggest that IKKε is involved in the NF-κB activation in PC cells through a positive feedback loop.

♦ PC cells with high level of NF-κB activity secrete a proteinaceous factor/factors that can induce NF-κB in cells with low level of NF-κB activity.

♦ We have generated more than 95 clones of DU145 and more than 80 clones of PC3 cells transfected with d.n. mutants of IKKα, IKKβ, IKKε, and IKKy.

♦ NFκB function was dramatically inhibited in PC cells stably transfected with d.n. IKKy and d.n. IKKβ mutants. D.n. IKKε mutant moderately affected NF-κB activation by selective NF-κB inducers.
Reportable outcomes

Manuscripts

Abstracts presented at national meetings

Seminar presentations by P.I.
1. Selenium compounds inhibit IκB kinase and transcriptional factor NF-κB in prostate cancer cells. Basic Science Conference, Division of Medical Oncology, University of Colorado Health Sciences Center, Denver, CO. February 2002.

Conclusions
Our data suggest that constitutive NF-κB activity in androgen-independent PC cells may be mediated through an autocrine/paracrine loops and through feedback loop involving IKKs. Our results also suggest that IKKγ and IKKβ play more important role in NF-κB transcriptional function in prostate cells.

References

Appendices
Selenium Compounds Inhibit IκB Kinase (IKK) and Nuclear Factor-κB (NF-κB) in Prostate Cancer Cells

Alexander V. Gasparian, Ya Juan Yao, Junxuan Lu, Alexander Y. Yemelyanov, Lyudmila A. Lyakh, Thomas J. Slaga, and Irina V. Budunova

AMC Cancer Research Center, Denver, Colorado 80214 [A. V. G., Y. J. Y., J. L., A. Y. Y., T. J. S., I. V. B.], and Laboratory of Cell Regulation and Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 [L. A. L.]

Abstract
Selenium compounds are potential chemopreventive agents for prostate cancer. There are several proposed mechanisms for their anticancer effect, including enhanced apoptosis of transformed cells. Because the transcription factor nuclear factor-κB (NF-κB) is often constitutively activated in tumors and is a key antiapoptotic factor in mammalian cells, we tested whether selenium inhibited NF-κB activity in prostate cancer cells. In our work, we used sodium selenite and a novel synthetic compound, methylseleninic acid (MSeA), that served as a precursor of the putative active monomethyl metabolite methylselenol. We found that both selenium forms inhibited cell growth and induced apoptosis in DU145 and JCA1 prostate carcinoma cells. Sodium selenite and MSeA, at the concentrations that induced apoptosis, inhibited NF-κB DNA binding induced by tumor necrosis factor-α and lipopolysaccharide in DU145 and JCA1 prostate cells. Both compounds also inhibited IκBα luciferase reporter activity in prostate cells. A key to NF-κB regulation is the inhibitory IκBα proteins that in response to diverse stimuli are rapidly phosphorylated by IκB kinase complex, ubiquitinated, and degraded, releasing NF-κB factor. We showed that sodium selenite and MSeA inhibited IκB kinase activation and IκBα phosphorylation and degradation induced by TNF-α and lipopolysaccharide in prostate cells. NF-κB blockage by IκBα d.n. mutant resulted in the sensitization of prostate carcinoma cells to apoptosis induced by selenium compounds. These results suggest that selenium may target the NF-κB activation pathway to exert, at least in part, its cancer chemopreventive effect in prostate.

Introduction
Prostate cancer is the second leading cause of cancer death in men in the United States. Despite significant improvement of hormonal, chemical, and radiation therapies, there is no cure for locally advanced or metastatic prostate cancer. Thus, studies to develop strategies for prostate cancer prevention continue to be essential. During the past two decades, selenium emerged as a factor with the most consistent anticancer effect among a number of micronutrients tested in animal experiments and clinical trials (1-7). Significantly, selenium appeared to be one of the most promising agents for prostate cancer prevention. The most convincing data have been obtained by Clark et al. (5) in a double-blind, placebo-controlled trial involving >1000 patients. Participants treated with a supranutritional dose of selenium in the form of selenized brewer's yeast for 4.5 years (200 μg of selenium daily, with the average daily intake of selenium in the United States ~100 μg) had substantial reductions in the incidence of prostate cancer, as well as total cancer incidence and mortality (3, 4). The follow-up for the cohort used in Clark's trial further indicated that selenium treatment decreased prostate cancer risk (8).

Selenium is an essential trace element nutrient and is a normal component of diets. The nutritional essentiality of selenium is linked to the functional activities of several enzymes and proteins that contain selenium, including glutathione peroxidases, thioredoxin reductases, and others (2, 9, 10). The chemopreventive activity of selenium is determined by its various covalent forms and metabolites. Over the past 15 years, several groups have focused on the identification of the active metabolite(s) that is critical in selenium cancer chemoprevention and on the search of less toxic forms of selenium that would retain its chemopreventive activity. Selenium is metabolized in vivo to a key proximal metabolite hydrogen selenide, which in turn undergoes sequential methylation to methylselenol and other methyl-selenium metabolites (1). Because methylation of hydrogen selenide produces forms of selenium that are not genotoxic (11), stable methylated selenium compounds are currently viewed as precursors or "pro-drugs" to release methylselenol and hold a high potential for cancer chemoprevention use. MSeA is one of such synthetic compounds that effectively inhibited tumor cell growth in vitro (12) and possessed strong antitumor activity in animal experiments (13).

Although several mechanisms including antioxidant protection (via glutathione peroxidases), altered carcinogen metabolism, enhanced immune surveillance, and inhibition of neoangiogenesis have been proposed to account for the anticancer effect of selenium (9, 11), induction of apoptosis

Received 12/26/01; revised 8/12/02; accepted 8/19/02.
1 Supported by Department of Defense Prostate Cancer Research Program DAMD17-01-1-0015.
2 These authors contributed equally to this work.

To whom requests for reprints should be addressed, at AMC Cancer Research Center, 1600 Pierce Street, Denver, CO 80214. Phone: (303) 239-3568; Fax: (303) 239-3560; E-mail: budunovai@amc.org.

The abbreviations used are: MSeA, methylseleninic acid; IκB, inhibitor of NF-κB; IKK, IκB kinase; LPS, lipopolysaccharide; NF-κB, nuclear factor-κB; PARP, poly(ADP-ribose) polymerase; GFP, green fluorescent protein; TNF, tumor necrosis factor; EMSA, electrophoretic mobility shift assay; EMSSA, electrophoretic mobility supershift assay; FL, Firefly luciferase; RL, Renilla luciferase.
of tumor cells by selenium may be of special significance in the chemoprevention of prostate cancer, which is known for very low proliferative activity (14). Because the transcription factor NF-κB is a key antiapoptotic factor in mammalian cells, we hypothesized that suppression of the NF-κB activation pathway may be related to selenium chemopreventive activity in prostate.

The active NF-κB complex is a homo- or heterodimer composed of proteins from the NF-κB/Rel family. In non-stimulated cells, NF-κB resides in the cytoplasm in a complex with the inhibitor protein, collectively called IκB (15, 16). Most agents that activate NF-κB use a common pathway based on the phosphorylation of the two NH₂-terminal serines in IκBα, IκBβ, and IκBε with subsequent ubiquitination and degradation of IκB proteins by the 26S proteasome (17-21). Degradation of IκBs results in nuclear translocation of released NF-κB dimers (p65/p50) and activation of target genes. Signal-induced phosphorylation of IκB is executed by the recently identified IKK complex containing IKKa and IKKβ and regulatory proteins (22).

Although selenium has a strong potential as chemopreventive agent for prostate, the mechanisms underlying its diverse biological effects have been studied mostly in other cancer cell models but not in prostate cells. To test our hypothesis that suppression of the NF-κB activation pathway may be involved in selenium chemopreventive activity in prostate, we studied the effect of two selenium compounds, selenite and MSeA, on NF-κB activity and upstream IKK kinases in prostate carcinoma cell lines in parallel with the effect of those compounds on prostate cell growth and apoptosis.

Materials and Methods
Cell Cultures and Treatments. In our work, we used two androgen-resistant prostate carcinoma cell lines, DU145 and JCA1. DU145 prostate cancer cells were purchased from American Type Culture Collection (Rockville, MD). JCA1 prostate cancer cells, originally established by Muraki et al. (23), were obtained from Dr. O. Rokhill (University of Iowa, Iowa City, IA). Both cell lines were cultured in RPMI 1640 (Life Technologies, Inc., Rockville, MD) supplemented with 10% FBS (HyClone, Logan, UT), 10 mM HEPES, 0.01 mM 2-mercaptoethanol, 2 mM l-glutamine, and antibiotics as described elsewhere (24). Cells were treated with LPS (from Escherichia coli 026:B6; Sigma Chemical Co, St. Louis, MO), TNF-α (R&D Systems, Minneapolis, MN), sodium selenite pentahydrate (J. T. Baker, Inc., Philipsburg, NJ), or MSeA (a generous gift from Dr. H. Ganter, University of Wisconsin at Madison, Madison, WI).

Effect of Selenium Compounds on Cell Accumulation and Apoptosis in Prostate Cell Cultures. To study the effect of selenium on cell accumulation, DU145 and JCA1 cells were plated on 35-mm dishes and cultured to 50% confluence. They were treated with MSeA or selenite at a concentration of 1–5 μM without medium change for 24 h. The number of cells in three dishes/treatment was determined.

We used PARP proteolysis and DNA fragmentation assays to determine apoptosis 24 h after the beginning of selenium treatment. Adherent cells and detached floating cells were combined for whole-cell protein extract preparations. PARP cleavage was estimated by Western blot analysis with PARP antibodies (PharMingen, San Diego, CA).

For DNA fragmentation assay, DNA was isolated from adherent cells and detached floating cells as described previously (12). Briefly, cells were lysed in a buffer containing 10 mM Tris-HCl (pH 8.0), 100 mM EDTA, 0.5% SDS, 0.5 mg/ml proteinase K, and digested at 50°C for 3 h. The lysate was extracted twice with phenol-chloroform. Nucleic acids were precipitated with isopropanol in the presence of 0.2 M NaCl. The pellet was resuspended in 30 μl of 10 mM Tris-HCl, 1 mM EDTA (pH 7.5), treated with RNase, and loaded onto 1.5% agarose gel containing 0.1 μg/ml ethidium bromide for electrophoresis. Gels were photographed using UV illumination.

NF-κB Blockage by Adenovirus Infection. Prostate carcinoma cells were seeded on 35-mm dishes and at 50% confluence were infected with type 5 recombinant adenovirus (AdV) construct AdV-d.n.IκBα encoding GFP and mutant human IκBα protein with substitution of serines 32 and 36 to alanines (S2A36A) or adenovirus encoding only GFP (AdV-control). AdV-d.n.IκBα virus with deletions of E1 and E3 was generated using the AdEasy1 system. The AdEasy1 system was a generous gift of Dr. T-C. He, (The Howard Hughes Medical Institute, Baltimore, MD). Mutations of IκBα were constructed by site-directed mutagenesis with the Bio-Rad Mutagen Kit (Montreal, Canada). Adenoviruses were purified by CsCl gradient centrifugation. Cells were infected with adenoviruses (10⁵ viral particles/dish) in 700 μl of medium with 0.5% serum overnight. Twenty-four h after infection, cells were treated with selenium compounds for 24 h.

Preparation of Nuclear and Cytosol Protein Extracts. Cells (20–25 × 10⁶) cells were used for each time point. Cells were washed and harvested in cold PBS. Cell pellets were resuspended in homogenization buffer, and nuclear and cytosolic protein extracts were prepared as described previously (25).

EMSA. The binding reaction for EMSA contained 10 mM HEPES (pH 7.5), 80 mM KCl, 1 mM EDTA, 1 mM EGTA, 6% glycerol, 0.5 μg of polyclonal anti-NF-κB antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). DNA-protein complexes were analyzed on 6% DNA retardation gels (Novex, Carlsbad, CA). Dried gels were subjected to autoradiography.
Transient Transfection and Measurement of Luciferase Activity. JCA1 prostate cells were plated on 35-mm dishes and at 50% confluency were cotransfected with Tfx-50 reagent (Promega Corp.) with 3× κB Luciferase reporter-FL under promoter with three copies of conventional κB site (Clontech Laboratories, Inc., Palo Alto, CA) and pRL-null construct-RL under minimal promoter (Promega Corp.). Tfx-50 reagent (2.5 μg of plasmid DNA) and the plasmid DNAs (both in doses of 2 μg/dish) were added to the dishes in antibiotic-free, serum-free medium. Twenty-four h after transfection, JCA1 cells were pretreated with selenium compounds for 30 min and treated with TNF-α for additional 6 h. Cells were harvested in the lysis buffer, and the luciferase activity was measured by dual luciferase assay (Promega Corp.) as recommended by the manufacturer. FL activity was normalized against Rl activity to equalize for transfection efficacy.

Western Blot Analysis. Nuclear or cytosol proteins were resolved by electrophoresis on 10–12.5% SDS-PAGE, depending on the size of the target proteins, and transferred to Immobilon-P membrane (Millipore Corp., Bedford, MA). Polyclonal anti-p65 (sc-372) and anti-κBα (sc-371) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-Ser32 κBα antibody was from Cell Signaling Technology, Inc. (Beverly, MA). Monoclonal PARP antibody that recognizes both PARP and cleaved PARP was purchased from Pharmingen. Membranes were blocked with 5% nonfat milk in TBST buffer [10 mM Tris HCl (pH 7.5), 150 mM NaCl, 0.05% Tween 20] and incubated with primary antibodies for 1.5 h at room temperature. Anti-phospho-Ser32 κBα antibody and PARP antibody required 6 h incubation at 4°C. Peroxidase-conjugated antirabbit or antimouse IgG (Sigma Chemical Co.) was used as a secondary antibody. ECL Western blotting detection kit (Amersham Pharmacia Biotech, Uppsala, Sweden) was used for protein detection. The membranes were also stained with Ponceau Red to verify that equal amounts of proteins were loaded and transferred. Quantitative analysis of Western blots was done by One-Decan gel and blot analysis software, Scanalytics, Inc. (Fairfax, VA).

In Vitro IKK Activity Assay. Cells were lysed in TNT buffer [20 mM Tris HCl (pH 7.5), 200 mM NaCl, 1% Triton X-100] with protease inhibitors (25). Immunoprecipitation of 450 μg of total protein was performed with 1 μl of rabbit IKKα (#1997) and IKKβ (#4137) antisera (a kind gift of Dr. N. R. Rice, National Cancer Institute, Frederick, MD) in 3 ml of TNT buffer. Two h later, 20 μl of protein A-Sepharose 4B (Sigma Chemical Co.) in TNT buffer were added to each sample and incubated with gentle rotation overnight. Immunoprecipitate was washed three times in TNT buffer with protease inhibitors and two times with kinase buffer without protease inhibitors. Kinase reaction was performed in kinase buffer [20 mM HEPES (pH 7.4), 2 mM MgCl2, and 2 mM MnCl2], containing 2 μCi of [γ-32P]ATP and κBα peptide (1–54) that has only Ser-32 and Ser-36 sites of phosphorylation (Boston Biologicals, Inc., Boston, MA) as a substrate for 30 min at 30°C. Then 2× Tricine/SDS sample buffer (Novex, Carlsbad, CA) was added to each reaction, and samples were boiled and subjected to electrophoresis on 10–20% gradient tricine PAAG (Novex). Gels were dried and exposed to film with an intensifying screen at −70°C.

Data in all figures are shown as results of representative experiments. All experiments were repeated at least three times.

Results

Effect of Selenium Compounds on Prostate Carcinoma Cell Growth and Apoptosis. Clark et al. (3) found that the average plasma selenium level in participants treated with a supernutritional dose of selenium in prevention trial was around 2.5 μM. To establish an effective dose of selenium compounds for NF-κB in vitro studies, we first tested the effects of selenite and MSeA in concentration ranging from 1 to 5 μM on cell growth in the DU145 and JCA1 prostate cell lines. Both selenium compounds inhibited cell accumulation within 24 h of treatment in a dose-dependent manner (Fig. 1). Selenite appeared to be more effective than MSeA in both cell lines; it inhibited cell accumulation at all tested concentrations (1–5 μM). MSeA substantially inhibited cell accumulation only at 5 μM.

Apoptotic effects of selenite and MSeA at 5 μM have been studied in DU145 cells using as end points PARP cleavage and DNA fragmentation. Caspase-mediated cleavage of PARP inactivates this enzyme and inhibits its ability to respond to DNA strand breaks for repair. PARP cleavage is now recognized as one of the most sensitive markers of caspase-mediated apoptosis. As shown in Fig. 2A, at 24 h of exposure both compounds induced PARP cleavage. Consistent with our early findings (12), MSeA induced PARP cleavage more effectively than sodium selenite. As shown in Fig. 2B, at 24 h of exposure both compounds strongly and to the same extent induced nucleosomal fragmentation typical of apoptotic cell death.

Selenium Compounds Inhibited NF-κB DNA Binding Activity. To determine whether inhibition of prostate cell growth and induction of apoptosis correlated with selenium effect on NF-κB function, we studied the effect of selenite and MSeA on NF-κB DNA binding in DU145 and JCA1 cell lines, both of which we have characterized previously with regard to the basal and inducible NF-κB activity (28). On the basis of the data presented above, we have chosen the 5 μM dose for both selenium compounds to study their effects on NF-κB activation in prostate cells.

Because of the greater growth inhibitory response of JCA1 cells to selenium treatment (Fig. 1), we examined this cell line first for the impact of 30-min selenium preexposure on the TNF-α-induced NF-κB DNA binding activity by EMSA. Consistent with our previous findings, TNF-α strongly induced NF-κB DNA-binding in JCA1 cells (Fig. 3). MSeA-exposed cells showed considerably inhibited κB-binding at 5 h of TNF-α stimulation, but this effect was abolished by 6 h (Fig. 3). On the other hand, selenite-exposed cells had nearly full κB-binding activity at 3 h of stimulation but displayed much less binding by 6 h, indicating a more delayed action than that of MSeA. Analysis of NF-κB binding complexes by EMSA revealed that the major NF-κB complex in JCA1 cells is represented by the p50/p65 heterodimer (Fig. 3C).
Selenium Inhibits NF-κB and IKK in Prostate Cells

Fig. 1. Effect of selenium compounds on cell number accumulation in prostate cell cultures. DU145 and JCA1 cells were seeded in 12-well plates. At 50% confluence, cells were treated with MSeA or selenite at the indicated concentrations without medium change. The average number of cells in 3 wells/treatment was determined 24 h after the beginning of treatment. Data are shown as a percentage of control (means; bars, SD) for one representative experiment.

Similar patterns of differential impacts of selenite and MSeA on TNF-α-induced NF-κB DNA binding activity were observed in DU145 cells (Fig. 4A). The kinetics of the inhibitory action and recovery in DU145 cells appeared to be faster than in JCA1 cells. Specifically, MSeA-exposed DU145 cells showed almost a complete block of NF-κB binding at 0.5 h of TNF-α stimulation but almost fully recovered the binding activity by 3 h of stimulation. On the other hand, selenite-exposed DU145 cells showed considerably less binding by 0.5 h of TNF-α stimulation, and this effect persisted for 3 h. Selenite and MSeA preexposure also inhibited NF-κB DNA binding induced by LPS (Fig. 4B).

Taken together, the data support an inhibitory effect of selenium preexposure on the inducible NF-κB DNA binding activity irrespective of the nature of stimulation. Furthermore,
To further investigate the selenium effect on NF-κB activity, we performed transient transfection experiments using prostate carcinoma JCA1 cells with an exogenous κB-responsive gene, κB-Luciferase reporter. Mindful of the apoptotic effects of prolonged selenium exposure, we have chosen 6-h exposure with both selenium compounds for these experiments. The results of transient transfection experiments presented in Fig. 6 correlated well with the EMSA results. Pretreatment with both selenium and MSeA at 5 μM significantly inhibited the luciferase activity induced by TNF-α in JCA1 cells.

**Selenium Inhibited TNF-α and LPS-Induced Activation of IKK.** As we have already mentioned, the absence of a direct effect of both selenium compounds on NF-κB DNA binding in a cell-free system (see Fig. 5) suggested that selenium affects some cellular steps in the NF-κB activation pathway. One of the first key stages to NF-κB binding is the phosphorylation of IκB inhibitory proteins by IKK kinases. Thus, in our next experiment, we studied whether selenium compounds affected IKK activation and IκB-α phosphorylation in DU145 cells.

As expected, TNF-α and LPS stimulation strongly increased IKK activity and increased the level of IκB-α phosphorylation in DU145 cells (Fig. 7). Selenite and MSeA at a concentration of 5 μM significantly inhibited IKK activation and subsequently IκB-α phosphorylation induced by TNF-α and LPS. It is important to mention that the kinetics of IKK inhibition by two different selenium compounds correlated well with kinetics of inhibition of κB DNA binding. The inhib-
NF-κB and IKK in Prostate Cells

As shown in Fig. 8, upon TNF-α treatment, p65 translocated to the nucleus in DU145 cells, and both selenite and MSeA inhibited this translocation. Consistent with the results on the repression of IkB DNA binding, the inhibitory effect of selenite on p65 translocation was more sustained than the effect of MSeA at 3 h.

Whether selenium compounds affected TNF-α-induced nuclear translocation of the p65 subunit of NF-κB was examined by Western blot analysis of DU145 cells pretreated with selenite and MSeA and treated with TNF-α. As we reported previously (26), TNF-α induced dramatic IkB-α degradation within 10–30 min with complete IkB-α resynthesis at later times of exposure in DU145 cells (Fig. 8). Both selenite and MSeA inhibited IkB-α degradation during the first 30 min of cell exposure to TNF-α (Fig. 8). At later times, the effect of selenium compounds on IkB-α level has not been revealed.

Selenium Decreased IkB-α Degradation and p65 Nuclear Translocation. As we showed above, both selenium compounds blocked IKK activation and IkB-α phosphorylation. This suggested that proteolytic degradation of IkB-α should be also affected by selenium compounds. To determine whether selenium compounds indeed inhibited IkB-α degradation, the cytoplasmic level of IkB-α has been examined by Western blot analysis in DU145 cells pretreated with selenite and MSeA and treated with TNF-α. As we reported previously (26), TNF-α induced dramatic IkB-α degradation within 10–30 min with complete IkB-α resynthesis at later times of exposure in DU145 cells (Fig. 8). Both selenite and MSeA inhibited IkB-α degradation during the first 30 min of cell exposure to TNF-α (Fig. 8). At later times, the effect of selenium compounds on IkB-α level has not been revealed.

We found that NF-κB blockage in DU145 cells by infection with adenovirus construct encoding mutant human IkBα protein (Adv-d.n.IkBα) resulted in increased sensitivity of prostate carcinoma cells to both selenium compounds. Indeed, the morphological changes in DU145 cells in response to selenium compounds, such as profound cell retraction, rounding, and detachment described in our previous work (12), occurred much earlier in cell cultures infected with adenovirus expressing IkBα mutant (data not shown).

As one could see in Fig. 9A, treatment of DU145 cells with sodium selenite or MSeA as well as cell infection with Adv-d.n.IkBα resulted in PARP cleavage (Fig. 9, Lanes 3, 4, and 5). It is important that selenium treatment of DU145 cells with blocked NF-κB resulted in more intensive PARP cleavage than in selenium-treated cells with intact, constitutively active NF-κB (Fig. 9, compare Lanes 3 and 6 and Lanes 4 and 7). Moreover, because of a reduced expression of full-length PARP in MSeA- and selenite-treated cells with blocked NF-
The expression of d.n. mutant. These data clearly indicate IKBO Bars, SD. Western blots in were quantified using One-Dscan gel and blot analysis for full-length PARP ratio. Amounts of PARP and cleaved PARP presented on B, effect of IKBO d.n. mutant and selenium compounds on cleaved PARP: A, Western blot analysis of PARP cleavage.

Fig. 9. Effect of IxBa d.n. mutant on PARP cleavage in prostate cells. DU145 prostate cells were infected with adenovirus expressing GFP and IxBa mutant lacking Ser-32 and Ser-36 (AdV-d.n. IxBa) or adenovirus expressing only GFP (AdV-control). Twenty-four h later, cell cultures were left untreated or treated with MSFeA (5 μM) or with sodium selenite (5 μM) for 24 h. PARP cleavage was detected by Western blotting with antibody, which detects the full-length PARP (116 kDa) and PARP cleavage product (85 kDa). Adherent cells and detached floaters were combined for whole-cell lysate preparations. A, Western blot analysis of PARP cleavage. B, effect of IxBa d.n. mutant and selenium compounds on cleaved PARP: full-length PARP ratio. Amounts of PARP and cleaved PARP presented on Western blots in A were quantified using One-Dscan gel and blot analysis software, Scanalytics, Inc. (Fairfax, VA). Ratios of absorbances for bands corresponding to cleaved PARP and full-length PARP are plotted. Bars, SD.

κB, the ratio of cleaved PARP:full-length PARP was much strongly affected in those cells than in cells that underwent other treatments (Fig. 9B). Thus, both the amounts of cleaved PARP and the ratio cleaved PARP:full-length PARP were much higher in cells where NF-κB activity was inhibited by the expression of IxBa d.n. mutant. These data clearly indicate that NF-κB blockage resulted in sensitization of prostate carcinoma cells to apoptosis induced by selenium compounds.

Discussion
Previous work has shown that selenite and MSFeA represent two distinct pools of selenium metabolites (11, 29). Selenite and other selenium compounds that are metabolized to hydrogen selenide (H₂Se) induced DNA single-strand breaks and subsequent cell death by combination of acute lysis and apoptosis in different tumor cell cultures (12). Interestingly, selenite-induced apoptosis does not require caspase activation (12). Thus, less active PARP cleavage in prostate carcinoma cells treated with sodium selenite (Fig. 2A) probably reflects this caspase-independent type of apoptosis. MSFeA and other immediate precursors of another major selenium metabolite, methylselenol, induced apoptosis mediated by caspase cascades (13) without genotoxicity and necrosis (11). In the work presented here, we have found that at an apoptotic dose, both sodium selenite and MSFeA inhibited κB DNA-binding and NF-κB transcriptional activity induced by TNF-α or LPS in two prostate cancer cell lines. Specifically, the two selenium forms showed a differential kinetics of NF-κB inhibitory action; the effect of MSFeA was more rapid and transitory, whereas selenite action was slower but persisted much longer. It is important to emphasize that NF-κB suppression by selenite, which exerted a more persistent effect on NF-κB function in comparison with the effect of MSFeA, correlated well with the stronger inhibition of cell accumulation by this selenium compound in both cell lines (Fig. 1). Our results obtained in prostate cells are consistent with previous experimental findings that selenite could inhibit κB DNA binding in other mammalian cells (27, 30) and provided further biochemical insights on underlying mechanisms. In our experiments, we showed for the first time that selenium compounds inhibited function of NF-κB transcription factor through the blockage of IKK activity, the kinase complex that phosphorylates IκB inhibitors, and consequently, triggers IκB degradation. It is important to emphasize that NF-κB blockage by IxBa d.n. mutant sensitized prostate carcinoma cells to apoptosis induced by selenium.

Although our research was focused on IKK as the important step necessary for NF-κB activation, there are other possible direct and indirect mechanisms of selenium effect on NF-κB function. It is known that selenium effects at lower doses are mediated by different selenium-proteins such as glutathione peroxidases, thioredoxin reductases, and others that have broad physiological functions including antioxidant protection and redox regulation of different protein activity (1, 31, 32). At higher doses, selenium can directly exert oxidation of nucleotides, proteins, and cofactors (1). One of the previously proposed mechanisms of the selenium effect on NF-κB activity is such a direct interaction between selenium and NF-κB, which results in adduct formation with the thiol groups of NF-κB proteins and subsequent alteration of NF-κB properties including DNA binding (27). The results of our experiments in cell-free system do not suggest that studied selenium compounds directly inhibit NF-κB DNA binding. Whether this discrepancy is caused by buffer conditions used in the test tube reactions or reflects a specific difference between cell types should be investigated.

How relevant are our findings in terms of cancer chemoprevention or therapeutic intervention by selenium?

(a) NF-κB factor activation has been associated with tumorigenesis. NF-κB is constitutively activated in human leukemias and lymphomas as well as in some solid tumors and in cell lines from human solid tumors including breast, ovar-
Selenium Inhibits NF-κB and IKK in Prostate Cells

Selenium, colon, thyroid, pancreatic, and urinary bladder carcinomas, melanomas, and others (15, 33–38). It was shown that inhibition of NF-κB activity in carcinoma cell lines could dramatically reduce cell growth and metastatic properties in vivo (39, 40). Recently, we found that NF-κB is activated in some prostate carcinoma cell lines because of an aberrant activation of IKK, resulting in an elevated basal level of IkB-α phosphorylation and turnover (28). These data suggest that constitutive activation of the NF-κB signaling pathway could be an important step during tumor development in prostate. Therefore, selenium inhibition of NF-κB activity during early stages of tumorigenesis, which are likely windows for chemoprevention, could be one mechanism mediating prostate cancer prevention and treatment.

(b) NF-κB plays a key role in cell protection against diverse apoptotic stimuli including chemotherapeutic and radiotherapeutic treatments through activation of the antiapoptotic gene program in cells (41). Antiapoptotic genes that are regulated by NF-κB include genes encoding Bcl-2-like proteins (Bcl-α1, Bcl-β, and Bcl-X), inhibitor of apoptosis proteins (IAP1, IAP2, and IAP3), and others (41). It became clear recently that NF-κB is also an important regulator of cell proliferation. There is some evidence that NF-κB proteins are implicated in cell cycle regulation through their effect on the cyclin-dependent kinase/cyclin-dependent kinase inhibitor system (42). The best explored link between NF-κB activation and cell cycle progression involves cyclin D1, a cyclin that is expressed early in the cell cycle and is crucial to commitment to DNA synthesis (43). It was shown that promoters of cyclins D1 and D2 contain κB binding sites and are important transcriptional targets of NF-κB (43). Therefore, inhibition of NF-κB antiapoptotic and proliferative activities could provide specific and causative links to inhibition of prostate tumor cell growth and survival by selenium compounds. In conclusion, this regard, it is important to mention that in vitro the growth of prostate cancer cells was much more affected by selenium compounds than the growth of primary prostate cells (45).

In conclusion, our study, as a proof of principle, established that an apoptotic dose of selenium exposure can inhibit NF-κB activation through the inhibition of IKK activity and IkB degradation. Because of the involvement of constitutive NF-κB signaling in cancer cell survival and proliferation, our findings suggest that this signal pathway may constitute a molecular target for selenium to exert its anticancer activity. In this regard, it is noteworthy that some other potential cancer preventive natural compounds including green tea polyphenols, phytoestrogen genistein, vitamin E derivatives, alliin, resveratrol, and curcumin have been also found to be inhibitors of NF-κB and IKK in different cells (46, 47). It will be important to further identify the specific inhibitory mechanisms by each of these diverse agents to build a mechanistic basis for combinatorial application of multiple agents to synergistically inhibit NF-κB signaling to achieve comprehensive prevention of prostate cancer.

Acknowledgments
We thank Dr. O. Rokhlin (University of Iowa, Iowa City, IA) for providing JCA1 cells; Dr. N. Rice (NCI, Frederick, MD) for the generous gift of 1xBoN, ILKα, and ILKβ antisera and technical support; and Dr. H. Ganther (University of Wisconsin, Madison, WI) for providing MSεA.

References

---

5 I. V. Budunova and Y. J. Yao, unpublished data.


American Association for Cancer Research

93rd Annual Meeting
April 6-10, 2002 • San Francisco, California
Volume 43 • March 2002

In joint sponsorship with the Keck School of Medicine of the University of Southern California

The premier meeting for cancer research in the post-genomic era
Featuring the latest developments in basic, translational, and clinical cancer research
Prostate carcinoma cells secrete a soluble factor(s) responsible for NF-κB activation. Alexander Gasparian, Alexander Yemelyanov, Ya Juan Yao, Dariusz Kowalczyk, and Irina Budunova. AMC Cancer Research Centre, Denver, CO.

We found recently that NF-κB is constitutively activated in human androgen-independent prostate carcinoma cell lines DU145, PC3, and JCA1 but not in normal prostate epithelial cells and androgen-dependent PC cell line LNCaP. It was shown that prostate carcinoma cells produce and secrete some cytokines and growth factors that are potential NF-κB activators. It is also known that some of these cytokines and growth factors are themselves regulated by NF-κB at the transcriptional level. We hypothesized that increased NF-κB activity in androgen-independent PC cells may be mediated by such factor(s) through an autocrine/paracrine loop. To test this hypothesis we incubated LNCaP cells with the conditioned medium of PC3 cells. Conditioned medium taken from PC3 cells induced IκBα phosphorylation as well as κB-binding in LNCaP cells. It also increased the expression of endogenous κB-responsive genes such as 1κB-α. The conditioned medium of DU145 and JCA1 cells did not affect NF-κB activity in LNCaP cells. Boiling and multiple freezing/thawing of PC3 conditioned media eliminated the effect of the medium on κB binding. This suggests that the secreted NF-κB inducer is a proteinaceous factor. The nature of the factor/factors that induce NF-κB is under study. Supported by DOD Prostate Cancer Research Program DAMD17-01-1-0015.
93rd Annual Meeting
April 6-10, 2002 • San Francisco, California
Volume 43 • March 2002

In joint sponsorship with the Keck School of Medicine of the University of Southern California

The premier meeting for cancer research in the post-genomic era
Featuring the latest developments in basic, translational, and clinical cancer research
Activation of NF-κB transcription factor by different inducers employs a common pathway. IκB inhibitory proteins, which retain NF-κB in the cytosol, are rapidly phosphorylated by IκB kinases (IKKs), ubiquitinated and undergo degradation. It became clear that NF-κB activation requires multiple distinct IKKs. IKKe (previously termed IKKi) is the only inducible IKK whose expression level is regulated by cytokines and possibly by NF-κB itself. This suggests that IKKe is involved in a positive autocrine loop of NF-κB activation. NF-κB transcription factor plays an important role in tumor development and is often constitutively activated in different tumor cells including androgen-independent prostate carcinoma (PC) cell lines (Gasparian, Budunova et al., 2001). The goal of this project was to study the role of IKKe in constitutive and inducible NF-κB activation in PC cells. Northern blot analysis revealed that IKKe is expressed in DU145 and PC3 cells, which have high constitutive levels of NF-κB activity, but not in primary normal prostate epithelial cells and in PC cell lines LNCaP and MDA PCa 2b which have low levels of NF-κB activity. IKKe transcription can be induced in PC cells by TNF-α treatment. The blockage of IKKe function by stable transfection of PC3 cells with IKKe dominant negative (d.n.) mutant K38A (Peters et al., 2000) resulted in the decrease of constitutive expression of endogenous κB-responsive genes IκB-α and IL6. The IKKe d.n. mutant also significantly affected NF-κB activation by selective NF-κB inducers such as IL-1 and TPA. On the other hand, IKKe d.n. mutation did not affect activation of NF-κB-binding by TNF-α even though the degradation of IκB-α in IKKe d.n.-transfected cells was significantly blocked in comparison to parental and empty vector-transfected PC3 cells. These data indicate that IKKe is necessary for NF-κB induction by selected NF-κB stimuli and possibly plays a significant role in constitutive activation of NF-κB factor in androgen-independent PC cells. Supported by DOD Prostate Cancer Research Program DAMD17-01-1-0015.